Tema Heart & Health ETF (HRTS)
| Assets | $53.61M |
| Expense Ratio | 0.75% |
| PE Ratio | 24.41 |
| Shares Out | 1.48M |
| Dividend (ttm) | $0.47 |
| Dividend Yield | 1.30% |
| Ex-Dividend Date | Dec 10, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 31.69% |
| Volume | 505 |
| Open | 36.21 |
| Previous Close | 36.24 |
| Day's Range | 36.21 - 36.29 |
| 52-Week Low | 29.54 |
| 52-Week High | 38.87 |
| Beta | 0.65 |
| Holdings | 47 |
| Inception Date | Nov 20, 2023 |
About HRTS
Fund Home PageThe Tema Heart & Health ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.
Top 10 Holdings
49.01% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 11.44% |
| Thermo Fisher Scientific Inc. | TMO | 5.71% |
| UnitedHealth Group Incorporated | UNH | 4.97% |
| Merck & Co., Inc. | MRK | 4.47% |
| Novo Nordisk A/S | NOVO.B | 4.19% |
| Roche Holding AG | RHHBY | 3.99% |
| Johnson & Johnson | JNJ | 3.99% |
| Revolution Medicines, Inc. | RVMD | 3.53% |
| Cytokinetics, Incorporated | CYTK | 3.38% |
| Gilead Sciences, Inc. | GILD | 3.35% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 10, 2025 | $0.47291 | Dec 11, 2025 |
| Dec 11, 2024 | $0.46931 | Dec 12, 2024 |
Performance
HRTS had a total return of 21.43% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.24%.
News
Tema ETFs Exceeds $5bn in AUM After Three Years
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since...
Tema ETFs Surpasses $2 Billion in AUM in Under Three Years
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced that the firm has surpassed $2 billion in assets under mana...
Tema Appoints ETF Industry Leader Steve Munroe as President
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this role,...
Tema Surpasses $1bn AUM Two Years After Launch, Strengthens Team With Key Growth Hires
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), has surpassed $1 billion in assets under management (AUM) in just two years since...
How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)
The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.
Looking at Next Gen of Weight Loss: Tema ETFs CEO
Tema Obesity & Cardiometabolic ETF (HRTS) currently holds 46 companies focused on GLP-1, obesity, and weight-loss. Tema ETFs CEO and Founder Maurits Pot says we're trying to build a product that goes ...
What's Next for Weight Loss Stocks?
Tema Obesity & Cardiometabolic ETF is up 4% year-to-date. David Song discusses health care and ETF investing.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Sign of top or next pop? Rush of new offerings spring up around Mag 7, weight loss
Sign of top or next pop? Rush of new offerings spring up around Mag 7, weight loss.
Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund
Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk and Eli Lilly , aiming to tap into growing demand for their weight-loss and diabetes drugs.